Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors

Blood

Volumn 100, Issue 2, 2002, Pages 585-593

  Liao, Albert T ^a,b   Chien, May B ^a,b   Shenoy, Narmada ^a,b   Mendel, Dirk B ^a,b   McMahon, Gerald ^a,b   Cherrington, Julie M ^a,b   London, Cheryl A ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SUGEN INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 [(5 CHLORO 2 OXO 1,2 DIHYDRO 3H INDOL 3 YLIDENE)METHYL] 2,4 DIMETHYL N (2 PYRROLIDIN 1 YLETHYL) 1H PYRROLE 3 CARBOXAMIDE; 5 [(5 CHLORO 2 OXO 1,2 DIHYDRO 3H INDOL 3 YLIDENE)METHYL] N [2 (DIETHYLAMINO)ETHYL] 2,4 DIMETHYL 1H PYRROLE 3 CARBOXAMIDE; 5 [(5 FLUORO 2 OXO 1,2 DIHYDRO 3H INDOL 3 YLIDENE)METHYL] 2,4 DIMETHYL N (2 PYRROLIDIN 1 YLETHYL) 1H PYRROLE 3 CARBOXAMIDE; FIBROBLAST GROWTH FACTOR RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; SU 11652; SU 11654; SU 11655; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; CELL CYCLE; CELL DEATH; CONTROLLED STUDY; DRUG INHIBITION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENZYME ACTIVE SITE; GENE MUTATION; LIGAND BINDING; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTO ONCOGENE;

EID: 0037100281     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2001-12-0350     Document Type: Article

References (85)

1. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family
2. The kit ligand, stem cell factor
3. The biology of stem cell factor and its receptor C-kit
4. d mice
5. V mice and their increase by bone marrow transplantation
6. d anemic mice
7. Identification, purification, and biological characterization of hematopoeitic stem cell factor from buffalo rat liver-conditioned medium
8. Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem cell factor
9. Candidate ligand for the c-kit transmembrane kinase receptor: KL, a fibroblast derived growth factor stimulates mast cells and erythroid progenitors
10. Mast cell lineage development and phenotypic regulation
11. Kit signal transduction
12. The Kit-activating mutation D816V enhances stem cell factor-dependent chemotaxis
13. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand independent activation of c-kit product
14. Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P815 generated by a point mutation
15. Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3
16. Identification of a point mutation in the catalytic domain of the proto-oncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder
17. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm
18. Systemic mastocytosis associated with acute myeloid leukaemia: Report of two cases and detection of the c-kit mutation Asp-816 to Val
19. A new c-kit mutation in a case of aggressive mast cell disease
20. c-kit mutation in a population of patients with mastocytosis
21. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis
22. Identification of activating c-kit mutations in adult-, but not in childhood-, onset indolent mastocytosis: A possible explanation for divergent clinical behavior
23. Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis
24. Epidemiological analysis of the most prevalent sites and types of canine neoplasia observed in a veterinary hospital
25. Mast cell tumors
26. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit
27. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways
28. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation
29. Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells
30. Systemic mastocytosis: Retrospective review of a decade's clinical experience at the Brigham and Women's Hospital
31. The treatment of mastocytosis: An overview
32. Mastocytosis: Diverse presentations and outcomes
33. Treatment of mastocytosis: Pharmacologic basis and current concepts
34. Treatment of systemic mast cell disorders
35. IFNα treatment in systemic mastocytosis
36. Response of severe systemic mastocytosis to interferon alpha
37. Treatment of three patients with systemic mastocytosis with interferon alpha-2b
38. Interferon alpha and systemic mastocytosls: Analysis of therapeutic efficacy in 6 cases
39. Systemic mastocytosis with extensive polypoid lesions in the intestines: Successful treatment with interferon-alpha
40. Anti-interferon-gamma antibodies in a patient undergoing interferon-gamma treatment for systemic mastocytosis
41. Long-term effect of interferon alpha treatment in mastocytosis
42. Interferon treatment of patients with chronic urticaria and mastocytosis
43. Inhibition of human mast cell growth and differentiation by interferon gamma-1 b
44. Gain-offunction mutations of c-kit in human gastrointestinal stromal tumors
45. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors
46. Gastrointestinal stromal tumors: Recent advances in understanding of their biology
47. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors
48. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors
49. Sarcoma
50. Gastrointestinal stromal tumor workshop
51. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: Biological and clinical implications
52. New approaches to therapy for mastocytosis: A case for treatment with kit kinase inhibitors
53. Classes of c-KIT activating mutations: Proposed mechanisms of action and implications for disease classification and therapy
54. Roots of clinical resistance to STI-571 cancer therapy
55. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
56. Roots of clinical resistance to STI-571 cancer therapy
57. Cancer research: Why some leukemia cells resist STI-571
58. Phase I experience with SU6668, a novel multiple receptor tyrosine kinase inhibitor in patients with advanced malignancies
59. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
60. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts
61. SUGEN kinase inhibitors SU5416 and SU11248 inhibit Flt3 signaling: Therapeutic application in AML
62. Clustering of activating mutations in c-KIT's juxtamembrane coding region of canine mast cell neoplasms
63. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia
64. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies: A study on a large series of patients and cell lines
65. Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia: The Children's Cancer and Leukemia Study Group, Japan
66. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SH P-1
67. Pl3 kinase mediates transformation of hematopoietic cells by the V816 c-kit mutant
68. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant
69. Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain
70. Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase
71. Inhibition of spontaneous receptor phosphorylation by residues in a putative alphahelix in the KIT intracellular juxtamembrane region
72. Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases
73. Design, synthesis, and evaluations of substituted 3-[(3- or 4- carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases
74. Identification of substituted 3-[(4,5,6, 7-tetrahydro-1 H-indol-2- yl) methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-R beta tyrosine kinases
75. Inhibition of tumor angiogenesis by synthetic receptor tyrosine kinase inhibitors
76. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
77. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase
78. Indolinone derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells
79. PKC412, a protein kinase inhibitor with a broad therapeutic potential
80. Induction of apoptosis and inhibition of small cell lung cancer growth by quinoxaline tyrphostins
81. Expression of c-kit receptor in normal and transformed human non-lymphoid tissues
82. Co-expression of the c-kit receptor and the stem cell factor in gynecological tumors
83. Coexpression of stem cell factor and its receptor c-kit in human malignant glioma cell lines
84. Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors
85. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571